This leader in small modular nuclear reactors saw its stock limp through the last two months of 2024. Did it ever recover?
Strong demand and clinical progress against high-incidence diseases, calls for gene therapy manufacturers to scale up ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback